Regeneron antibody drug appears effective at preventing COVID The trial entailed injecting 1,505 people not infected with the SARS-CoV-2 virus but living in households with people carrying the virus with the Regeneron antibody cocktail or a placebo. Picture: 123rf.com
57 minutes ago
ZURICH, Switzerland - US biotech firm Regeneron and its Swiss partner Roche unveiled promising clinical trial results on Monday indicating that an antibody treatment used to treat COVID-19 patients also helps prevent infections.
The results of the Phase 3 trial showed that the combination of the antibodies casirivimab and imdevimab dramatically reduced the risk of symptomatic infection among people living with COVID-19 patients, Roche said in a statement.
Regeneron to seek U.S. OK for COVID-19 cocktail to be used for prevention By John Miller
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company s Westchester campus in Tarrytown
ZURICH (Reuters) -Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.
REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company.
Philogen S.p.A.: Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS
(i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer
SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce a publication describing the development and the
in vivo characterization of OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper entitled An Ultra-High Affinity Small Organic Ligand of Fibroblast Activation Protein for Tumor Targeting Applications was published in the peer-reviewed journal
ZURICH (Reuters) Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.
REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week and 93% after that, according to trial data released by the company.
In a separate trial, Regeneron also said the treatment reduced overall risk of progressing to symptomatic COVID-19 by 31% and by 76% after the third day.
Regeneron has enlisted Switzerland s Roche and its massive biotech facility in South San Francisco to make around 2 million doses annually. The cocktail already has emergency U.S. approval for mild to moderate COVID-19 patients, and the companies are hoping the latest trials convince regulators to expand deployment.
Date Time
FIFA welcomes decision of Zurich Labour Court upholding dismissal of Markus Kattner
In a judgment of 10 March 2021, after a case lasting almost five years, the Zurich Labour Court held that the 2016 dismissal of Markus Kattner, former FIFA Acting Secretary General, was justified and appropriate.
The Court determined that, given the breaches of loyalty committed by this former employee, it would have been inconceivable to allow him to continue working at FIFA. Consequently, his dismissal without notice was fully justified.
Mr Kattner initially claimed over CHF 10 million from FIFA as “compensation” for alleged wrongful termination. This claim was based on an employment contract signed with him by the previous FIFA administration on 31 May 2015 (four days after the arrests of numerous football officials at the Baur au Lac Hotel in Zurich). That claim was rejected in full by the Court.